India, Feb. 15 -- On Thursday, shares of Applied Therapeutics, Inc. gained 16 percent after the clinical-stage biopharmaceutical company announced the positive interim 12-month results from the ongoing Phase 3 INSPIRE trial, in which the primary endpoints and several key secondary endpoints were achieved.
Currently, Applied Therapeutics stock is climbing 16.04 percent, to $3.11 over the previous close of $2.68 on a volume of 3,752,156. It had traded between $0.757 and $4.42 for the past 52 weeks on the Nasdaq.
The Phase 3 INSPIRE trial is a double-blind placebo-controlled registrational study for the patients with Sorbitol dehydrogenase deficiency, or SORD deficiency, which is a progressive, debilitating hereditary neuropathy that affects...